Steve Rees,
Vice President,
AstraZeneca
Steve Rees is currently Vice-President of Screening Sciences and Sample Management at AstraZeneca with global responsibility for High Throughput Screening, Compound Management, the human tissue BioBank and the provision of SAR biology support to preclinical discovery projects. Prior to joining AstraZeneca, Steve worked at GlaxoSmithKline for 24 years in various roles including that of Director of the Screening and Compound Profiling Department at GlaxoSmithKline in Stevenage. Steve has been responsible for developing hit identification, compound profiling and compound management strategies for AstraZenenca and previously GlaxoSmithKline. Steve has led multiple international collaborations and has sponsored the development and implementation of a range of cellular assay technologies for ion channel, GPCR and other target classes.
Steve has authored >60 scientific papers and has spoken at many international symposia including three occasions at the Society of Laboratory Automation and Screening (SLAS). He is currently Chair of the SLAS Europe Council . He is a member of the BBSRC panel of experts and is a member of the Board of Directors of ELRIG.
|
|
Strategies for the Identification of Lead Molecules to Sustain a Discovery OrganizationTuesday, 17 June 2014 at 10:00  Add to Calendar ▼2014-06-17 10:00:002014-06-17 11:00:00Europe/LondonStrategies for the Identification of Lead Molecules to Sustain a Discovery OrganizationDrug Discovery and Development - Online Event in VirtualVirtualSELECTBIOenquiries@selectbiosciences.comTo address the challenge of the delivery of quality drug-like molecules for lead optimization AstraZeneca has created a portfolio of hit identification methods and open innovation partnerships to deliver a sustainable lead optimization pipeline.
|
